What Agomab Therapeutics NV's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 10 | 10 |
| Sells | 0 | 0 |
| Total trades | 10 | 10 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 46,000 | 46,000 |
| Disposed | 0 | 0 |
| Net activity | +46,000 | +46,000 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Epstein David R | Director | Oct 21 | Open-market buy · P | +5,000 | $8.90 | +$44.5K | 25,000 |
| Epstein David R | Director | Oct 21 | Open-market buy · P | +5,000 | $8.86 | +$44.3K | 20,000 |
| Epstein David R | Director | Oct 08 | Open-market buy · P | +5,000 | $8.90 | +$44.5K | 15,000 |
| Epstein David R | Director | Oct 06 | Open-market buy · P | +5,000 | $8.70 | +$43.5K | 10,000 |
| Knotnerus Tim Jasper | Chief Executive Officer | Oct 06 | Open-market buy · P | +5,000 | $8.70 | +$43.5K | 21,823 |
| Kemula Pierre Thadee Victor | Chief Financial Officer | Oct 06 | Open-market buy · P | +2,000 | $8.54 | +$17.1K | 10,000 |
| Kemula Pierre Thadee Victor | Chief Financial Officer | Oct 06 | Open-market buy · P | +5,000 | $8.57 | +$42.9K | 8,000 |
| Kemula Pierre Thadee Victor | Chief Financial Officer | Oct 06 | Open-market buy · P | +3,000 | $8.67 | +$26K | 3,000 |
| Epstein David R | Director | Oct 05 | Open-market buy · P | +5,000 | $8.57 | +$42.9K | 5,000 |
| Knotnerus Tim Jasper | Chief Executive Officer | Oct 05 | Open-market buy · P | +6,000 | $8.48 | +$50.9K | 16,823 |
Loading...
